Our Science
CellRep’s platform uses AI to predict, validate, and optimize small molecules for cell rejuvenation through iterative in silico, in vitro, and in vivo cycles.
cellrep.bioCrawled Oct 30, 2026
CellRep’s platform uses AI to predict, validate, and optimize small molecules for cell rejuvenation through iterative in silico, in vitro, and in vivo cycles.
CellRep describes cells as specialized micro-factories with biological systems that perform specific functions. The company modifies cellular behavior for therapeutic use.
CellRep highlights a shared issue in cancer, HIV, and hepatitis therapies: exhausted immune cells that fail to function properly.
GRIDX’s investment enabled the company to assemble an AI/ML/GenAI team with top talent, including Julian Ganzabal, a longtime collaborator in AI development since 1994.
Alfonso is an entrepreneur with 28 years of experience in technology and business growth, including early leadership in IT projects and data center services.
Julian is an Electronic Engineer and Machine Learning specialist focused on the full ML lifecycle, including MLOps, model design, and teaching at ITBA.
Manuel is a Medical Doctor and PhD in Immunology with postdoctoral training at Stanford University, specializing in vaccine and immunotherapy research.
Luca Gattinoni directs research in T cell immunology and cancer at the University of Regensburg and the Leibniz Institute for Immunotherapy.
Soledad works across AI models, in vitro validation, and in vivo studies, with expertise in innate immune responses from her PhD at the University of Buenos Aires.
CellRep develops an AI-powered platform to discover small molecules that reprogram exhausted cells, restoring function without altering genetic code.
Transforming The Future of Cell Therapies
CellRep collects user data for privacy-compliant biotechnology research and development, storing it with industry-standard security protocols.